OPKO director granted options on 30,000 shares

OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock.

Rhea-AI Filing Summary

OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, were granted on June 18, 2026, and become exercisable starting June 18, 2027 with an expiration date of June 17, 2036. Following this grant, she holds stock options for 30,000 shares directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Yu Alice Lin-Tsing

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Key Figures

Option grant size: 30,000 shares Exercise price: $1.42 per share Grant price paid: $0.00 per option +4 more

7 metrics

Option grant size 30,000 shares Stock Option (Right to Buy) grant on June 18, 2026

Exercise price $1.42 per share Conversion or exercise price for stock options

Grant price paid $0.00 per option Awarded as compensation, no purchase price

Underlying shares 30,000 shares Common stock underlying the stock options

Post-transaction derivative holdings 30,000 options Total shares following transaction for this option award

Exercise start date June 18, 2027 Date options become exercisable

Expiration date June 17, 2036 Option expiration for the grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, conversion_or_exercise_price, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

conversion_or_exercise_price financial

"conversion_or_exercise_price: "1.4200""

underlying security financial

"underlying_security_title: "Common Stock""

expiration_date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OPKO Health (OPK) report for Alice Lin-Tsing Yu?

OPKO Health reported that director Alice Lin-Tsing Yu received a grant of stock options for 30,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of the new OPKO Health (OPK) stock options?

The granted stock options have an exercise price of $1.42 per share. This means Yu can choose to buy OPKO common shares at $1.42, regardless of the market price, once the options become exercisable.

When do Alice Lin-Tsing Yu’s OPKO Health (OPK) options vest and expire?

The stock options become exercisable starting June 18, 2027 and expire on June 17, 2036. After expiration, any unexercised options cease to be valid and can no longer be used to acquire shares.

How many OPKO Health (OPK) options does the director hold after this Form 4?

Following the reported grant, Yu holds stock options for 30,000 shares of OPKO common stock directly. This reflects the entire amount from the new award as shown in the filing’s post-transaction holdings field.

Was the OPKO Health (OPK) Form 4 transaction a market buy or sell?

No, the Form 4 shows a grant, award, or other acquisition of stock options coded as “A.” It is a derivative award given at a price of $0.00, not an open-market share purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 05:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Alice Lin-Tsing

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FLORIDA 33137

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.42	06/18/2026		A		30,000		06/18/2027	06/17/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

	Steven D. Rubin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)